



Michigan Medicine Laboratories

1500 East Medical Center Drive
Ann Arbor, MI 48109
(800) 862-7284 (734) 936-2598

ANATOMIC PATHOLOGY CONSULTATION REPORT

| | | |
|------------------------|-------------------|--|
| Order Number: | OC-20-7548 | Referred by: |
| First Name: | JOHN | DR. BAKER |
| Last Name: | SMITH | GENERAL HOSPITAL |
| MRN: | 123456789 | 123 MAIN ST. |
| Gender: | Male | Age: 49 Y DOB: 11/1/1970 |
| Date Received: | 03/26/2020 | ANYWHERE, MI 48001 |
| Date Completed: | 04/07/2020 | |

DIAGNOSIS:

Left kidney, radical nephrectomy (SR20:OS:1392; 3/19/20): Low-grade renal cell carcinoma (3.4 cm by gross), type unclassified with oncocytic features. Tumor involves perinephric adipose tissue. Benign adrenal gland with nodular hyperplasia. Margins negative. See letter for details.

Dear Dr. Baker,

Thank you for sending this case in consultation. I have reviewed the provided material from your above-named patient, a 49-year-old man who underwent left radical nephrectomy on 3/19/20.

As you can see above, I completely agree with your impression in this case. The H&E slides demonstrate sections of renal parenchyma involved by a low-grade epithelioid neoplasm comprised of cells with abundant eosinophilic (oncocytic) cytoplasm, slightly enlarged and irregular nuclei, and small nucleoli, arranged predominantly in sheets of variably-sized nests with focal admixed acinar/tubular formation and scattered psammomatous calcifications within variably hyalinized edematous stroma. Provided immunostains show that tumor cells express pan-cytokeratin (AE1/AE3; focal to patchy), CK7 (focal to patchy), PAX8, CD117, and E-cadherin but are negative for TTF-1, CD10, and RCC antigen expression. Additional immunohistochemistry performed at our institution demonstrates that tumor cells express CK7 (focal to patchy), CD117, S100A1, and vimentin (patchy) but are negative for CA-IX, HMB-45, and Melan-A expression; FH and SDHB immunostain show retained cytoplasmic staining in tumor cells. Overall, in my opinion, these morphologic features and immunohistochemical results are consistent with a low-grade renal cell carcinoma, type unclassified with oncocytic features, as the overall findings are beyond my threshold for renal oncocytoma. Regardless, I would expect this tumor to behave in an indolent manner with a low risk of recurrence and/or metastatic dissemination.


I have taken the liberty to share this case with my colleague Dr. Priya Kunju, who shares my interest in genitourinary pathology, and she agrees with the above interpretation.

Again, thank you for sending this case in consultation. I appreciate the opportunity to participate in the care of this patient. Please do not hesitate to contact me with any additional questions or concerns.

First Name: JOHN
Last Name: SMITH
Order Number: OC-20-7548
Date Received: 03/26/2020

Clinic: ABCD

Sincerely,



Aaron Mark Udager, M.D., Ph.D.

House Officer(s):

EMAN ABDULFATAH

Materials Received:

A Outside Case Number: SR20:OS 1392
Materials Received: Number of prepared slides: 16
Number of unstained slides: 0
Number of blocks: 1 Additional 4/3/20

CPT Codes:

| Specimen | CPT Code | Number of Charges |
|----------|----------|-------------------|
| A | 88321 | 1 |
| A | 88341 | 8 |
| A | 88342 | 1 |

Laboratory Accrediting Agency Compliance Statement:

If immunostain testing was performed on this case, the testing was developed and the performance characteristics were determined by the University of Michigan Clinical Immunoperoxidase Laboratory. It has not been cleared or approved by the U.S. Food and Drug Administration. (The FDA has determined that such clearance is not necessary. This test is used for clinical purposes. It should not be regarded as investigational or for research.) Appropriate negative and positive controls were run and demonstrated expected results. Most antibodies (including ER, PR, and HER2/neu) were not validated on decalcified tissues; negative staining on decalcified specimens should therefore be viewed with discretion, as a falsely negative result cannot be excluded. The Coreo ACIS instrument (if used for any test on this case) is FDA approved.

Performing site:

ULAB University of Michigan Hospitals, Main Medical Campus
1500 E Medical Center Dr
Ann Arbor, MI 48109

CLIA Director: Riccardo Valdez, MD

CLIA Number: 23D0366712

First Name: JOHN
Last Name: SMITH
Order Number: OC-20-7548
Printed on: 3/7/2020 12:30:19P

Clinic: ABCD